Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Core Insights - Clearside Biomedical is advancing suprachoroidal drug delivery as a transformative method for treating macular diseases, with six abstracts accepted for presentation at the ARVO 2025 Meeting [1][2] Company Developments - The company’s proprietary formulation, CLS-AX, a suspension of axitinib, shows potential as a long-acting therapy for wet age-related macular degeneration (AMD), demonstrating durability and safety in clinical trials [2][5] - The SCS Microinjector allows for targeted delivery of therapeutics directly to the retina, enhancing the precision and applicability of treatments [1][6] - Clearside is planning a Phase 3 program for CLS-AX and is also evaluating other small molecules for treating geographic atrophy [7] Research and Presentations - Six abstracts related to the suprachoroidal drug delivery platform will be presented at the ARVO 2025 Meeting, covering topics such as the efficacy of CLS-AX and advancements in training models and segmentation algorithms [1][3][4] - Notable presentations include top-line results from the ODYSSEY Phase 2b study and a literature review on the evolving role of suprachoroidal drug delivery [3][4] Technology and Innovation - The SCS injection platform provides unprecedented access to the back of the eye, allowing for a non-surgical procedure that could improve patient outcomes [6][7] - The SCS Microinjector is designed with custom features to optimize drug administration, potentially reducing toxic effects on non-diseased cells [6]